Shane Schaffer

Shane Schaffer is the co-founder, Chairman, and CEO of Cingulate Therapeutics, headquartered in Kansas City, Kansas. This Phase 3 clinical-stage biopharmaceutical company is known for developing and managing innovative pharmaceutical products aimed at treating Attention Deficit/Hyperactivity Disorder (ADHD) and other therapeutic areas such as anxiety disorders and insomnia.

With a 25-year track record in the pharmaceutical industry, he specializes in drug development and commercialization. He is recognized for his entrepreneurial leadership in various business facets, such as product launches and brand management. He earned his doctoral degree in Pharmacy from the University of Kansas in 1999. Further, he honed his expertise during a postdoctoral fellowship at Rutgers University’s College of Pharmacy, collaborating with Pfizer Worldwide Marketing and Morris Plains teams.

During his tenure at Pfizer Worldwide Marketing in New York, NY, he played a pivotal role as a Marketing Manager, spearheading the creation of the Global Communications Intranet and enhancing communication between medical and marketing teams. In Morris Plains, New Jersey, he took on significant responsibilities as a Project Manager and External Research Manager, overseeing Phase IV Medical Research and advancing training programs.

His career further evolved with managerial roles at major pharmaceutical firms such as Pfizer, Novartis, and Sanofi. At Novartis, he passionately managed the Ritalin® LA and Focalin™ segments, launching with substantial budget achievements and creating robust product awareness. His exemplary work across multiple product launches at Novartis earned him several prestigious awards.

At Sanofi, he led impactful initiatives during the company’s mergers and joint ventures, significantly contributing to the strategies and promotional campaigns for Avapro and Avalide. He also managed promotion for Hyalgan, Eligard, and Arixtra, maintaining high sales performance and securing multiple Sanofi Star Awards.

Post Sanofi, he joined M|C Communications LLC in Boston as a consultant, managing business operations for numerous primary pharmaceutical targets. In July 2009, he established Sabre Scientific Solutions, LLC, offering consulting services to the pharmaceutical and biotechnology sectors, emphasizing commercials, clinical operations, and product launches.

In January 2013, his entrepreneurial spirit led him to establish Cingulate Therapeutics LLC, which focuses on innovative drug-delivery technologies for ADHD and anxiety disorders. This venture recently partnered with Indegene to market its phase-3 oral ADHD medication, CTx-1301 and plans to submit a new drug application by mid-2025.

Beyond his professional realm, Shane Schaffer actively participates in philanthropic activities, notably with the Folds of Honor Charity, which provides educational support to the children of fallen or disabled military personnel. His dedication to his career and philanthropy underscores his broad impact on the pharmaceutical industry and community welfare.